Provided by Tiger Trade Technology Pte. Ltd.

Oric Pharmaceuticals Inc.

8.22
-0.9000-9.87%
Post-market: 8.06-0.1600-1.95%18:50 EST
Volume:1.55M
Turnover:13.06M
Market Cap:800.54M
PE:-4.85
High:9.23
Open:9.14
Low:8.20
Close:9.12
52wk High:14.93
52wk Low:3.90
Shares:97.39M
Float Shares:60.66M
Volume Ratio:1.26
T/O Rate:2.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6957
EPS(LYR):-1.8335
ROE:-39.73%
ROA:-25.23%
PB:1.97
PE(LYR):-4.48

Loading ...

Oric Pharmaceuticals Currently Down Eight Consecutive Days, On Track for Longest Losing Streak Since June 2024 -- Data Talk

Dow Jones
·
Yesterday

ORIC Pharmaceuticals (ORIC): Valuation Check After Encouraging Enozertinib Phase 1b Lung Cancer Data

Simply Wall St.
·
Dec 09

Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush

Dow Jones
·
Dec 08

Oric Pharmaceuticals Grants Stock Options and Restricted Stock Units to New Employees

Reuters
·
Dec 06

Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Dec 06

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 06

Oric Pharmaceuticals Reports Promising Phase 1b Results for Enozertinib in NSCLC Patients with EGFR Mutations

Reuters
·
Dec 05

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

GlobeNewswire
·
Dec 05

Oric Pharmaceuticals Showcases Enozertinib Data at ESMO Asia Congress 2025

Reuters
·
Dec 04

Oric® Pharmaceuticals Announces Enozertinib (Oric-114) Late-Breaking Oral Presentations in Egfr Atypical and Egfr Exon 20 Nsclc at the Esmo Asia Congress 2025

THOMSON REUTERS
·
Dec 04

ORIC Pharmaceuticals (ORIC): Assessing Valuation as New Enozertinib Clinical Data Sparks Investor Interest

Simply Wall St.
·
Dec 02

Oric Pharmaceuticals Unveils Phase 1b Data for Enozertinib in HER2 Exon 20 NSCLC at ESMO Asia 2025

Reuters
·
Dec 01

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

GlobeNewswire
·
Nov 25

Stock Track | Oric Pharmaceuticals Surges 5.92% Pre-market on Positive Analyst Coverage

Stock Track
·
Nov 20

Oric Pharmaceuticals Initiated at Outperform by Evercore ISI Group

Dow Jones
·
Nov 20

Oric Pharmaceuticals initiated with an Outperform at Evercore ISI

TIPRANKS
·
Nov 20

ORIC Pharmaceuticals Q3 Net Income USD -32.587 Million

Reuters
·
Nov 20

Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Nov 20

Oric Pharmaceuticals Initiated at Peer Perform by Wolfe Research

Dow Jones
·
Nov 19

Oric Pharmaceuticals price target raised to $20 from $17 at JPMorgan

TIPRANKS
·
Nov 18